LIXT Projected Dividend Yield

Lixte Biotechnology Holdings, Inc. ( NASDAQ : LIXT )

Lixte Biotechnology Holdings is a drug discovery company that uses biomarker technology to identify enzyme targets associated with diseases and then designs compounds to attack those targets. Co.'s product pipeline is focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. Co. is developing two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors, designated by Co. as the LB-100 series of compounds, and histone deacetylase inhibitors, designated by Co. as the LB-200 series of compounds. Co.'s focus is on the clinical development of the LB-100 series of compounds.

20 YEAR PERFORMANCE RESULTS